Press Releases Latest Jun 02, 2023 Theratechnologies Receives FDA Agreement to Amended Trial Protocol for its Lead PDC Candidate Sudocetaxel Zendusortide Press Releases Year None20232022202120202019201820172016201520142013 Jun 02, 2023 Theratechnologies Receives FDA Agreement to Amended Trial Protocol for its Lead PDC Candidate Sudocetaxel Zendusortide May 25, 2023 Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023 May 09, 2023 Theratechnologies Reports on its Annual Meeting of Shareholders May 04, 2023 Theratechnologies’ Trogarzo® (Ibalizumab-uiyk) Shortens Time to HIV Undetectability and Extends Durability of Undetectability and Viral Suppression in a Matched Treatment Comparison Apr 18, 2023 Theratechnologies Data Presentations at AACR 2023 Showcase Potential of Sudocetaxel Zendusortide as a Single Agent and in Combination with other Anticancer Therapies Apr 12, 2023 Theratechnologies Reports Financial Results and Business Updates for First Quarter 2023 Apr 03, 2023 Theratechnologies to Announce First Quarter 2023 Financial Results and Provide Business Update Mar 14, 2023 Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model Mar 07, 2023 Theratechnologies Receives Nasdaq Notification Letter Regarding Share Price Feb 28, 2023 Theratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022 Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 1 - 10 of 312
Jun 02, 2023 Theratechnologies Receives FDA Agreement to Amended Trial Protocol for its Lead PDC Candidate Sudocetaxel Zendusortide
Jun 02, 2023 Theratechnologies Receives FDA Agreement to Amended Trial Protocol for its Lead PDC Candidate Sudocetaxel Zendusortide
May 25, 2023 Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023
May 04, 2023 Theratechnologies’ Trogarzo® (Ibalizumab-uiyk) Shortens Time to HIV Undetectability and Extends Durability of Undetectability and Viral Suppression in a Matched Treatment Comparison
Apr 18, 2023 Theratechnologies Data Presentations at AACR 2023 Showcase Potential of Sudocetaxel Zendusortide as a Single Agent and in Combination with other Anticancer Therapies
Apr 03, 2023 Theratechnologies to Announce First Quarter 2023 Financial Results and Provide Business Update
Mar 14, 2023 Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model
Feb 28, 2023 Theratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022